Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

CVR Medical Corp V.CVM.H

Alternate Symbol(s):  CRRVF

CVR Medical Corp. is a medical technology organization. The Company is focused on the development and advancement of technology at work within the healthcare sector. The Company’s Carotid Stenotic Scan (CSS) is a diagnostic tool designed to detect and determine a level of carotid narrowing for the purpose of identifying patients at risk for Ischemic Stroke. The CSS provides a synergistic tool which complements other stroke screening technology, such as Duplex Doppler ultrasound (DUS), magnetic resonance angiography (MRA), and computed tomography angiography (CTA). The CSS is 100% non-invasive and does not require the use of harmful dyes. It offers its product to patients, payers, and healthcare providers. The CVR device uses only sound wave analysis to detect the presence of arterial stenosis.


TSXV:CVM.H - Post by User

Bullboard Posts
Comment by Looneytuneson Dec 02, 2019 5:36pm
157 Views
Post# 30414965

RE:Will this ever trade again?

RE:Will this ever trade again?I'm sure there is an expecttion that come January 2020, things will be the same as they were in January 2019; ie, that trading will just resume on the TSX, and that we will be on the verge of resubmission to the FDA; however lets take a look at what needs to happen before that :

1 - Funding; the company is effectively broke and interim funding needs to be found to enable all subsequent things to happen.
2- Management structure - maybe assume that either Dallas of Jim D;Orta will take over as CEO and that the structure needs to be the same as before ie with a COO; a qualified CFO etc.  Also re-recruit any specialist resources formerly employed by CVR Global.
3 - pay for the results of ongoing trials to be completed and the results released.
4- pay for the additional data as requested by the FDA to be collected and validated.
5 - Additional electrical testing by TUV (and pay for it) last time it took months to complete but at that time TUV were backlogged with testing of other devices; hopefully it will be a bit quicker this time.
6 - Prepare and submit full year accounts (the ones that were late last time).
7 - Persuade the TSX that the company is financially stable - not sure that we will be able to do that without substantial additional funding.

so my expectation for 2020 is that all the above will happen but probably not complete until June (and that the requirements fou funding will see at least a 100% dilution; but that's OK given the massive potential of the CSS) and that FDA submission will happen mid year; with commercialisation from January 2021. Sorry if that all sounds rather negative but feel that its realistic, and quite frankly, I'd rather we get it right this time.
Bullboard Posts